I have allergic conjunctivitis that isn't getting better — I used Tacrolimus and it didn't help — Will Xolair solve the problem?
When symptoms or doubts arise involving Allergic ConjunctivitisDistinguishing between scientifically validated information and palliative care makes all the difference in the evolution of respiratory, skin, and systemic health. This page aims to deepen understanding of... "I have allergic conjunctivitis that isn't getting better — I used Tacrolimus and it didn't help — Will Xolair solve the problem?", providing clear context on how the immune system reacts, which signs require medical attention, and how to structure individualized and effective care.
✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project
Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.
Difficult-to-Control Allergic Conjunctivitis: The Use of Tacrolimus and the Role of Xolair
Allergic conjunctivitis is a chronic inflammatory eye condition that can cause intense discomfort, redness, itching, and photophobia. In more severe or difficult-to-control cases, where conventional treatments and the use of topical corticosteroids do not provide the expected relief, therapeutic management becomes a challenge for both the patient and the attending physician. The use of calcineurin inhibitors in the form of eye drops or ophthalmic ointments, such as tacrolimus, is frequently evaluated by specialists for refractory cases, requiring rigorous ophthalmological and immunological monitoring.
A recurring question among patients who do not improve with traditional therapies is the possibility of using immunobiologicals, such as omalizumab (commercially known as Xolair). It is essential to understand that Xolair is a highly effective monoclonal antibody, widely licensed and indicated for the treatment of severe allergic asthma and chronic spontaneous urticaria. However, its use for the isolated treatment of allergic conjunctivitis is not yet officially indicated in the product information leaflet.
Although some scientific articles and reports in the medical literature point to the off-label use—that is, based on scientific evidence but outside the approved indications—of monoclonal antibodies in severe and refractory forms of allergic conjunctivitis, this practice is not part of the routine clinical practice of most specialists. For consideration of such treatment, the patient must be evaluated at a referral center for allergy and immunology.
If the medical team assesses the appropriateness of an approach based on advanced scientific evidence for extreme cases, the process requires ethical and regulatory rigor, including:
- Detailed evaluation by a specialized medical board;
- Justified use of a drug not licensed for this specific purpose (off-label);
- Signing of a consent and responsibility form by the patient or legal guardian, ensuring understanding of the risks and benefits.
We emphasize that this content is strictly educational and informative in nature, and in no way replaces in-person medical consultation, accurate diagnosis, and individualized follow-up with a specialist in Allergy, Immunology, or Ophthalmology.
Developments in Evidence-Based Medicine: Pharmacology of Immunobiologics and Precision Medicine
In Evidence-Based Medicine, the indication of immunobiological agents (monoclonal antibodies and receptor fusion proteins) It is based on the patient's inflammatory endotyping. Selective blocking of molecular targets — such as the neutralization of free IgE by omalizumab (in severe allergic asthma and chronic spontaneous urticaria refractory to quadrupled-dose H1 antihistamines), the dual inhibition of IL-4 and IL-13 interleukin signaling by dupilumab (In moderate to severe atopic dermatitis, eosinophilic/Th2 asthma, and chronic rhinosinusitis with nasal polyposis), the blockade of the TSLP epithelial alarm by tezepelumab or blocking the IL-5/IL-5R pathway — allows control of the inflammatory cascade at its cellular origin, reducing exacerbations and sparing the patient from the adverse metabolic, endocrine, and cardiovascular effects of prolonged systemic corticosteroid use.
💎 Diamond Plan — Eyes and ears free from recurring allergic inflammation. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Precision Medicine: How Monoclonal Antibodies and Immunobiologics Work
Selective Blockade of Cytokines (IL-4, IL-5, IL-13, TSLP) and Immunoglobulin E
Monoclonal antibodies (immunobiologics) have revolutionized the management of severe allergic and immune-mediated diseases that do not achieve full control with conventional therapies. Unlike systemic corticosteroids and classic immunosuppressants—which broadly depress immunity and generate metabolic toxicity—immunobiologics act as highly precise molecular keys, neutralizing specific targets of the inflammatory cascade: such as circulating free IgE (omalizumab), the IL-4 and IL-13 receptor (dupilumab), the eosinophilic pathway of IL-5 (mepolizumab and benralizumab), or the epithelial alarmin TSLP (tezepelumab).
Indications Criteria, Allergy Phenotyping, and Associated Therapies
Specialized monitoring integrates laboratory biomarkers, allergy test Targeted management of the upper and lower airways. Depending on the identified endotype, align targeted therapies with established strategies. allergy vaccine and rhinitis treatment It provides sustained clinical remission without the adverse effects of oral corticosteroids.
Mast Cell Activation, Histamine, and the Bradykinin Pathway
When isolated recurrent angioedema occurs without surrounding pruritic plaques, immunological reasoning must distinguish histaminergic conditions from those mediated by bradykinin—including hereditary or acquired angioedema due to functional or quantitative deficiency of C1-esterase inhibitor (C1-INH) and reactions induced by angiotensin-converting enzyme (ACE) inhibitor antihypertensive drugs. This differentiation is vital because bradykinin-related angioedema does not respond to conventional antihistamines or corticosteroids.
Diamond Plan: Specialized Allergy Treatment Wherever You Are
Treating the cause of an allergy requires consistency — and consistency requires access. Diamond Plan It was designed for patients throughout Brazil who face the high cost of allergy vaccines and the difficulties of travel, offering specialized follow-up via telemedicine and easy access to immunotherapy treatment. Eyes and ears free from recurrent allergic inflammation.
Why do patients across Brazil choose the Diamond Plan?
- Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
- easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
- A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
- Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
- National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.
More than 30 years caring for people with allergies.
Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.
START TODAY
Your expert consultation is just a click away.
I want to join the Diamond Plan.Schedule a teleconsultation
Official telemedicine environment: brasilsemalergia.online
Do you prefer to be served in person?
Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:
- Rio de Janeiro: Realengo (West Zone), North Zone, Duke of Caxias, Xerém, New Iguaçu, Itaguaí, Niterói, Iguaba Grande and Saint Peter of the Village (Lakes Region).
- São Paulo: Campo Limpo (South Zone).
- Paraná: Curitiba.
Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.
The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Conclusion and Summary of Guidelines
In summary, the appropriate approach to Allergic Conjunctivitis It requires a clear understanding of the immunological mechanisms involved, precise etiological diagnosis, and individualized medical follow-up. Avoiding self-medication and investigating the root cause of symptoms—relying on specialized resources and reliable guidance such as specialized allergy and immunology care when clinically relevant—is the safest way to control flare-ups, prevent complications, and ensure sustainable quality of life.
Scientific references and authoritative sources
The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information:




